Max S. Schlaak
Expertise in
10
conditions

Max S. Schlaak

Kerpener Str. 62, 
Koeln, NW, DE 
Expertise in
10
conditions
Kerpener Str. 62, 
Koeln, NW, DE 

Overview

Max Schlaak practices practicing medicine in Koeln, Germany.

Mr. Schlaak is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Metastatic Uveal Melanoma, Melanoma, Uveal Melanoma, Cutaneous T-Cell Lymphoma (CTCL), and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 149 peer reviewed articles and participating in 3 clinical trials.

Gender

Male

Locations

Kerpener Str. 62, Koeln, NW 50937, Germany
Other Locations
Kerpener Str. 62, Koeln, NW 50927, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
Enrollment Status: Completed
Publish Date: March 17, 2026
Intervention Type: Biological, Drug
Study Drugs: IMCgp100, Dacarbazine, Ipilimumab, Pembrolizumab
Study Phase: Phase 2
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma
Enrollment Status: Withdrawn
Publish Date: July 24, 2024
Intervention Type: Drug
Study Drugs: IMCgp100, Durvalumab, Tremelimumab
Study Phase: Phase 1/Phase 2
Adjuvant Nivolumab Treatment in Stage II High-risk Melanoma - A Randomized, Controlled, Phase III Trial With Biomarker-based Risk Stratification
Adjuvant Nivolumab Treatment in Stage II High-risk Melanoma - A Randomized, Controlled, Phase III Trial With Biomarker-based Risk Stratification
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2024
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 3
View 2 Less Clinical Trials

149 Total Publications

Five-year survival with tebentafusp in metastatic uveal melanoma.
Five-year survival with tebentafusp in metastatic uveal melanoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 02, 2026

Frequently Asked Questions about Max S. Schlaak

Is Max S. Schlaak a top-rated expert for Metastatic Uveal Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Max S. Schlaak is classified as an Distinguished expert for Metastatic Uveal Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Max S. Schlaak participate in research or clinical trials?

Yes. Max S. Schlaak has published 149 articles and abstracts on conditions like Metastatic Uveal Melanoma. You can view a list of Max S. Schlaak's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Schlaak's expertise for a condition
ConditionClose
    View All 17 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile